298 related articles for article (PubMed ID: 22205734)
1. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
Melchers M; Bontjer I; Tong T; Chung NP; Klasse PJ; Eggink D; Montefiori DC; Gentile M; Cerutti A; Olson WC; Berkhout B; Binley JM; Moore JP; Sanders RW
J Virol; 2012 Mar; 86(5):2488-500. PubMed ID: 22205734
[TBL] [Abstract][Full Text] [Related]
2. Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice.
Liu J; Clayton K; Gao W; Li Y; Zealey C; Budylowski P; Schwartz J; Yue FY; Bie Y; Rini J; Ostrowski M
Vaccine; 2020 Feb; 38(9):2149-2159. PubMed ID: 32014267
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.
Isik G; Sliepen K; van Montfort T; Sanders RW
PLoS One; 2014; 9(9):e107683. PubMed ID: 25247707
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
5. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
6. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
[TBL] [Abstract][Full Text] [Related]
7. Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.
Quinnan GV; Onabajo O; Zhang P; Yan L; Mattapallil JJ; Zhang Z; Dong M; Lu M; Montefiori D; LaBranche C; Broder CC
PLoS One; 2014; 9(5):e98060. PubMed ID: 24846288
[TBL] [Abstract][Full Text] [Related]
8. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.
Melchers M; Matthews K; de Vries RP; Eggink D; van Montfort T; Bontjer I; van de Sandt C; David K; Berkhout B; Moore JP; Sanders RW
Retrovirology; 2011 Jun; 8():48. PubMed ID: 21689404
[TBL] [Abstract][Full Text] [Related]
9. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
[TBL] [Abstract][Full Text] [Related]
10. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
11. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
13. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
Sellhorn G; Kraft Z; Caldwell Z; Ellingson K; Mineart C; Seaman MS; Montefiori DC; Lagerquist E; Stamatatos L
J Virol; 2012 Jan; 86(1):128-42. PubMed ID: 22031951
[TBL] [Abstract][Full Text] [Related]
14. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.
Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW
J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426
[TBL] [Abstract][Full Text] [Related]
15. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
16. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
17. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
20. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
